Nuveen LLC Acquires New Position in Theravance Biopharma, Inc. $TBPH

Key Points

• Nuveen LLC acquired 374,952 shares of Theravance Biopharma, Inc., valued at approximately $3,348,000, increasing its ownership to about 0.75% as of the latest reporting period.
• Several institutional investors have also increased their stakes in Theravance Biopharma, with over 99.10% of the stock currently owned by such investors.
• Analysts have upgraded Theravance Biopharma's stock ratings, with a consensus target price of $21.33 and multiple firms issuing "strong-buy" ratings.

Nuveen LLC purchased a new stake in Theravance Biopharma, Inc. (NASDAQ:TBPH - Free Report) in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 374,952 shares of the biopharmaceutical company's stock, valued at approximately $3,348,000. Nuveen LLC owned 0.75% of Theravance Biopharma as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. GSA Capital Partners LLP grew its holdings in shares of Theravance Biopharma by 11.9% in the 1st quarter. GSA Capital Partners LLP now owns 182,350 shares of the biopharmaceutical company's stock valued at $1,628,000 after buying an additional 19,363 shares during the period. Rhumbline Advisers boosted its stake in Theravance Biopharma by 3.8% in the 1st quarter. Rhumbline Advisers now owns 62,254 shares of the biopharmaceutical company's stock worth $556,000 after purchasing an additional 2,293 shares during the period. Price T Rowe Associates Inc. MD boosted its stake in Theravance Biopharma by 16.8% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 64,795 shares of the biopharmaceutical company's stock worth $610,000 after purchasing an additional 9,315 shares during the period. Bank of New York Mellon Corp boosted its stake in Theravance Biopharma by 1.5% in the 1st quarter. Bank of New York Mellon Corp now owns 117,499 shares of the biopharmaceutical company's stock worth $1,049,000 after purchasing an additional 1,720 shares during the period. Finally, ProShare Advisors LLC acquired a new position in Theravance Biopharma in the 4th quarter worth $119,000. Institutional investors and hedge funds own 99.10% of the company's stock.

Insider Activity at Theravance Biopharma

In other news, SVP Rhonda Farnum sold 24,000 shares of the firm's stock in a transaction that occurred on Monday, June 2nd. The shares were sold at an average price of $11.00, for a total transaction of $264,000.00. Following the transaction, the senior vice president directly owned 336,918 shares of the company's stock, valued at approximately $3,706,098. This trade represents a 6.65% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders have sold 44,000 shares of company stock worth $491,800 over the last quarter. 6.90% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on the stock. Wall Street Zen upgraded shares of Theravance Biopharma from a "hold" rating to a "strong-buy" rating in a research note on Saturday, August 16th. BTIG Research upped their target price on shares of Theravance Biopharma from $24.00 to $25.00 and gave the company a "buy" rating in a report on Friday, June 27th. Jones Trading raised shares of Theravance Biopharma to a "strong-buy" rating and set a $24.00 target price on the stock in a report on Tuesday, June 17th. Finally, Zacks Research raised shares of Theravance Biopharma from a "hold" rating to a "strong-buy" rating in a report on Friday, August 15th. Two investment analysts have rated the stock with a Strong Buy rating and two have given a Buy rating to the company's stock. According to data from MarketBeat, the stock has a consensus rating of "Strong Buy" and a consensus price target of $21.33.

Theravance Biopharma Trading Down 0.6%

TBPH stock traded down $0.09 during mid-day trading on Friday, hitting $13.88. 781,455 shares of the company were exchanged, compared to its average volume of 471,005. The business has a 50 day simple moving average of $11.80 and a 200-day simple moving average of $10.29. The stock has a market capitalization of $699.00 million, a PE ratio of 57.83 and a beta of 0.01. Theravance Biopharma, Inc. has a 1-year low of $7.88 and a 1-year high of $14.30.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology. In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.